Results 161 to 170 of about 15,755 (201)

Hematuria and Proteinuria in a Patient with Monoclonal Gammopathy of Renal Significance. [PDF]

Kidney360
Zhang M, Fu Y, Chen XJ.
europepmc   +1 more source

Combined Anti-CD20/Anti-CD38 Therapy in Posttransplant Focal Segmental Glomerulosclerosis Recurrence: A Retrospective, International, Multicenter Study. [PDF]

Transplant Direct
Cravedi P, Maggiore U, Mortari G, Alberici F, La Manna G, Goes N, Bouvier N, Comai G, Mehr AP, Gentile M, Palmisano A, Gessaroli E, Barbuto S, Caridi G, Bigatti C, Magnasco A, Bossini N, Kajana X, Spennacchio A, Gallon L, Ghiggeri GM, Vincenti F, Hullekes FE, Mehta RV, Riella LV, Verrina EE, Angeletti A.   +26 more
europepmc   +1 more source

Daratumumab Treatment for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): A Case Report. [PDF]

Ann Clin Transl Neurol
Zhang X, Zhao J, Zhao X, Hu X, Xiao Z, Wu J, Li X, Xu J, Li YJ.   +8 more
europepmc   +1 more source

Efficacy and Safety of Daratumumab, Lenalidomide and Dexamethasone Therapy in the First Relapse of Multiple Myeloma Patients - Real World Data from Hungary. [PDF]

J Hematol
Lovas S, Obajed Al-Ali N, Farkas K, Pinczes LI, Varga G, Mikala G, Rajnics P, Kosztolanyi S, Plander M, Pettendi P, Varoczy L.   +10 more
europepmc   +1 more source

Breakthroughs of bispecific antibodies therapy in multiple myeloma: latest updates from 2025 ASH. [PDF]

Biomark Res
Zhao B, Bu Q, Chen AL, Zhu HH.
europepmc   +1 more source

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study [PDF]

, 2019
Ahmadi, T, Arkenau, HT, Boccadoro, M, Cavenagh, J, Chen, D, Chiu, C, de Boer, C, Gay, F, Krejcik, J, Laubach, JP, Minnema, MC, Moreau, P, Perrot, A, Plesner, T, Richardson, PG, Schecter, JM   +15 more
core  

Why We Do Not Recommend That People With High-Risk Smoldering Myeloma Receive Treatment. [PDF]

Am J Hematol
Mohyuddin GR, Lemieux M, Chakraborty R, Gertz M.   +3 more
europepmc   +1 more source

Quadruplet daratumumab in combination with bortezomib, lenalidomide, and dexamethasone as front-line regimen improved clinical outcomes in high-risk myeloma patients in China: a multi-centered prospective real-world study. [PDF]

BMC Cancer
Cheng L, Liang D, Jia J, Zhang R, Yang Y, Liu P, Sun H, Qin X, Ma Y, Wu Y, Wang H, Zhuang J.   +11 more
europepmc   +1 more source

Outcomes of patients with systemic light chain amyloidosis treated with DVD front-line therapy. [PDF]

Cardiooncology
Wang J, Li M, Liao P, Tan J, Zeng L, Liu S, Wu P, Zeng P, Weng J, Du X, Zhong L, Lai P.   +11 more
europepmc   +1 more source